2016

Showing 9 posts of 9 posts found.

regeneron

Eylea sales jump helps boost Regeneron in Q2 results

August 5, 2016
Medical Communications, Research and Development 2016, Eylea, Q2, Regeneron, results

Regeneron Pharmaceuticals has published positive Q2 results with a 27% rise in Eylea (aflibercept) sales in the US helping to …

pfizer_reflection

Revenue rises at Pfizer as Ibrance and Xeljanz beat sales expectations

August 2, 2016
Research and Development, Sales and Marketing 2016, Pfizer, Prevnar, Q2, Xeljanz, ibrance, results

Pfizer has published its Q2 results, which show revenues rising 11% with new drugs helping to drive the growth and …

sanofi_hq_reception_close

Earnings drop at Sanofi as it looks for a quick Medivation resolution

July 29, 2016
Medical Communications, Research and Development 2016, Medivation, Q2, Sanofi, earnings

Sanofi has published its earnings results for Q2, which show a fall in sales and profits as their diabetes division …

astrazeneca_building_white

Cholesterol drugs drag AstraZeneca’s profits down in latest financial results

July 28, 2016
Research and Development, Sales and Marketing 2016, AstraZeneca, Q2, h1, results

AstraZeneca has maintained its financial outlook for 2016, despite its Q2 and H1 results showing sharp falls in core earnings …

gilead-sciences

Gilead lowers full-year guidance as sales and profits down in Q2

July 26, 2016
Manufacturing and Production, Research and Development, Sales and Marketing 2016, Gilead, Q2, results

Gilead Sciences has announced its financial results from the second quarter of this year, with sales and profits taking a …

roche_dark_0

Roche beats forecasts in strong H1 results

July 21, 2016
Research and Development, Sales and Marketing 2016, Q2, Roche, h1, results

Roche has published very encouraging full results for the first half of this year, with cancer drug sales helping to …

jj_sign_on_wall

J&J boosted by pharma revenue in Q2 results

July 20, 2016
Research and Development 2016, Johnson and Johnson, Q2, results

Shares at Johnson and Johnson have reached a record high of over $125 after pharma revenues helped to raise full …

novartis_side_building

Novartis lowers core operating profit outlook in Q2 results

July 19, 2016
Manufacturing and Production, Research and Development, Sales and Marketing 2016, Novartis, Q2, results

Novartis has warned that its profits may decline this year as it issued second quarter results, with generic competition for …

sanofi_hq__boetie_hall

Sanofi confirm 2016 outlook with Q1 results, EPS rises 5.3%

April 29, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2016, Q1, Sanofi, earnings, outlook, results

Sanofi (EPA: SAN) has confirmed its outlook for 2016 with the publication of their first quarter results, with earnings per …

Latest content